S
Serina Therapeutics, Inc. (SER)
ASE – Real Time Price. Currency in USD
1.63
+0.03 (1.88%)
At close: May 12, 2026, 3:59 PM EDT
1.74
+0.10 (6.29%)
Pre-market: May 13, 2026, 9:17 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
1.63
+0.03 (1.88%)
At close: May 12, 2026, 3:59 PM EDT
1.74
+0.10 (6.29%)
Pre-market: May 13, 2026, 9:17 AM EDT
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
| Name | Position |
|---|---|
| Dr. Balkrishan Gill Ph.D. | Executive Co-Chairman of the Board |
| Dr. J. Milton Harris Ph.D. | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board |
| Dr. Joshua Thomas Ph.D. | Head of Chemistry |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |
| Dr. Srini Tenjarla Ph.D. | Chief Technical Operations Officer |
| Mr. Gregory S. Curhan | Chief Financial Officer |
| Mr. Steven A. Ledger | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-04-28 | DEFA14A | a2026proxydefa14a.htm |
| 2026-04-27 | DEF 14A | ser-20260427.htm |
| 2026-04-21 | 8-K | ser-20260415.htm |
| 2026-04-17 | PRE 14A | ser-20260417.htm |
| 2026-03-27 | 10-K/A | ser-20251231.htm |
| 2026-03-25 | S-8 | forms-8.htm |
| 2026-03-23 | 8-K | ser-20260317.htm |
| 2026-01-30 | S-3 | forms-3.htm |
| 2026-01-28 | 8-K | ser-20260127.htm |
| 2026-01-15 | 8-K | ser-20260109.htm |